Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
IgG4-related kidney disease Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 IgG4-related kidney disease indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
IgG4-related sialadenitis Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 IgG4-related sialadenitis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
IgG4-related ophthalmic disease Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 IgG4-related ophthalmic disease indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Idiopathic hypertrophic pachymeningitis Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Idiopathic hypertrophic pachymeningitis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Retroperitoneal fibrosis Indication Strategy Report 2026: CD20, Trials and Deals
30 July 2026
2026 Retroperitoneal fibrosis indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Multifocal fibrosclerosis Indication Strategy Report 2026: TGF-beta, Trials and Deals
30 July 2026
2026 Multifocal fibrosclerosis indication strategy covering epidemiology, TGF-beta biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Rhupus syndrome Indication Strategy Report 2026: BAFF, Trials and Deals
30 July 2026
2026 Rhupus syndrome indication strategy covering epidemiology, BAFF biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Remitting seronegative symmetrical synovitis with pitting edema Indication Strategy Report 2026: IL-6, Trials and Deals
30 July 2026
2026 Remitting seronegative symmetrical synovitis with pitting edema indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet…
Latest Hotspot
8 min read
Synovitis acne pustulosis hyperostosis osteitis syndrome Indication Strategy Report 2026: IL-17, Trials and Deals
30 July 2026
2026 Synovitis acne pustulosis hyperostosis osteitis syndrome indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Chronic recurrent multifocal osteomyelitis Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Chronic recurrent multifocal osteomyelitis indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Familial cold autoinflammatory syndrome Indication Strategy Report 2026: IL-1, Trials and Deals
30 July 2026
2026 Familial cold autoinflammatory syndrome indication strategy covering epidemiology, IL-1 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Otulipenia Indication Strategy Report 2026: TNF, Trials and Deals
30 July 2026
2026 Otulipenia indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market attractiveness.